Asia-Pacific Long Read Sequencing Market – Industry Trends and Forecast to 2030

Asia-Pacific Long Read Sequencing Market, By Technology (Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Synthetic Long Read Sequencing, and Others), Product (Instruments, Consumables, and Services), Application (Whole Genome Sequencing, Epigenetics, RNA Sequencing, Complex Population, Targeted Sequencing, Identification and fine mapping of structural variation, Tandem Repeat Sequencing, Pseudogene discrimination, Resolving allele phasing, Reproductive genomics, Cancer, Viral and Microbial Sequencing and Others), Workflow (Pre-Sequencing, Sequencing, and Data Analysis), End-user (Academic and Research Institutes, Clinical Laboratories, Hospitals, Pharma and Biotech Entities and Others) – Industry Trends and Forecast to 2030.

Asia-Pacific Long Read Sequencing Market Analysis and Size

Sickle cell anaemia is a severe hereditary disease that affects about 72,000 new-borns. The cases of inherited single gene-affected genetic illnesses are alpha and beta-thalassemia, which are the most prevalent. The WHO estimates that some 8,000 pregnancies are at risk annually in Iran, where the condition is highly prevalent. In addition, as the need for early diagnosis increases, the long read sequencing market is anticipated to expand due to the prevalence of genetic illnesses that affect DNA, RNA and protein synthesis including colour blindness, Down syndrome, cystic fibrosis.

Data Bridge Market Research analyses that the long read sequencing market which is USD 4977.70 million in 2022, is expected to reach USD 27822.87 million by 2030, at a CAGR of 24.00% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asia-Pacific Long Read Sequencing Market Scope and Segmentation

Market Definition

Long read sequencing is commonly known as third-generation sequencing. This is a method for large-scale data analysis. Using this technology, DNA atoms may be sequenced in real-time producing lengthy reads. Without PCR amplification, these sequencing reactions are commonly authorized. Nanopore sequencing and single molecule real-time (SMRT) sequencing are two long read sequencing methods.

Asia-Pacific Long Read Sequencing Market Dynamics

Drivers

• Rising use of long-read sequencing

The market growth is accelerating due to many benefits in long-read sequencing over short-read or second-generation sequencing techniques. For instance, long reads from single-molecule real-time sequencing (SMRT) are utilized to discover diverse genetic and structural variants and offer a thorough picture of the complete genome. In 2015, experts predicted that hundreds of bacterial and viral genomes might be assembled using long read sequencing. In addition, growing consumer awareness of long-read sequencing and greater R&D spending are driving market expansion.

• Rising utilization of sequence analysis methodologies

One of the main reasons propelling market expansion is the rising acceptance of contemporary medical diagnostic techniques. The mobility and real-time speed of LRS technology also contribute to its rising appeal. A precise reference map of chromosome centromeres is also produced using it. Additionally, several biotech companies are creating cutting-edge technologies that combine a fresh approach to library preparation with tools for genome analysis. The value of LRS technology in locating novel harmful mutations in human diseases with unidentified genetic origins has been shown in a number of research. This provides a wealth of opportunities for researchers to use whole-genome sequencing (WGS) technology to advance medical genetics.

Opportunities

• The surge in incidences of genetic disorders

In the upcoming years, the prevalence of genetic disorders will fuel market expansion. About 100,000 Americans suffer from sickle cell disease, according to the Centers for Disease Control and Prevention. Many important companies will be interested in the progress of patients, which is anticipated to fuel the market's expansion.

Restraints/Challenges

• Higher cost per base relative to short-read sequencing

The long-read sequencing market is faced with difficulties because of a shortage of state of the art genetic testing facilities, costly installation procedures and a dearth of professionals with sophisticated diagnostic skills. The cost of sequencing is calculated per base pair, and the sequencing depth and length are often balanced. Comparing long read sequencing to short read sequencing, the former frequently provides worse coverage, a higher error rate and a higher cost per base.

This long read sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the long read sequencing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2019, Oxford Nanopore developed Flongle in 2019 to analyze short DNA/RNA sequences quickly. Flongle is a desktop GridION X5 and portable MinION sequencing adaptor. Small Flange cells with a sequence data capacity of up to 1.8 Gb and headroom for up to 3 Gb. This product promotion helps the company consolidate its product portfolio.
• In 2020, For scientists working with large genomic DNA fragments, Promega Corporation released the Wizard HMW DNA Extraction Kit in 2020. Using this kit, researchers can obtain DNA fragments that improve performance in long read sequencing applications in 90 minutes. As a result, the company's product portfolio has become more appealing, appealing and advanced.

Asia-Pacific Long Read Sequencing Market Scope

The long read sequencing market is segmented on the basis of technology, product, workflow, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

    Technology

• Nanopore Sequencing
• Single Molecule Real Time Sequencing (SMRT)

Product

• Consumables
• Instruments
• Services

Workflow

• Sequencing
• Data Analysis
• Pre-Sequencing

Application

• Whole Genome Sequencing
• Epigenetics
• RNA Sequencing
• Complex Population
• Tandem Repeat Sequencing

• Identification and Fine Mapping of Structural Variation
• Viral and Microbial Sequencing
• Reproductive Genomics
• Pseudogene Discrimination
• Others

End User

• Hospitals and Clinics
• Pharmaceutical and Biotechnology Industry
• Others

 Long Read Sequencing Market Regional Analysis/Insights

The long read sequencing market is analyzed and market size insights and trends are provided by country, technology, product, workflow, application and end-user as referenced above.

The countries covered in the long read sequencing market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

China is dominating the Asia-Pacific long read sequencing market as it will have the largest market share by 2020. The Asia-Pacific long read sequencing market is also expanding due to an increase in the number of companies and the increasing adoption of clinical sequencing and analysis. It has been observed that China, Japan and Australia have adopted next generation sequencing technologies for disease diagnosis whereas underdeveloped countries such as South Korea, India, and others are increasing adoption of clinical sequencing and analysis, which again acts as a major factor for the growth of the Asia-Pacific long read sequencing market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Long Read Sequencing Market Share Analysis

The long read sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to long read sequencing market.

Some of the major players operating in the long read sequencing market are:

• Illumina, Inc. (U.S.)
• MicrobesNG (U.S.)
• Roche Sequencing (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• PacBio (U.S.)
• Oxford Nanopore Technologies plc (U.K.)
• Quantapore, Inc. (U.S.)
• FG Technologies (Switzerland)
• BaseClear B.V (Netherlands)
• INSTITUTE OF INTEGRATIVE CELL BIOLOGY AND PHYSIOLOGY (France)
• The Garvan Institute (Australia)
• France Génomique (France)
• Takara Holdings Inc. (Japan)
• Genexa AG (Switzerland)